|Day Low/High||0.49 / 0.52|
|52 Wk Low/High||0.48 / 2.93|
Dr. James Cardia, RXi's Director of Business Development and Intellectual Property, will take over the management of the Company's ongoing business development and partnering initiatives
RXi Pharmaceuticals is a collaborator on this grant and will receive a portion of the allotted funding for the development of sd-rxRNA therapeutic compounds targeting PTEN
The forum brings together leading family offices, high net worth private investors, pharma and foundations to explore the latest innovations transforming healthcare.
Study RXI-109-1501 is evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases
RXI-231 is in development as a cosmetic ingredient that may improve the appearance of uneven skin tone and pigmentation
Forum brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences
RXI-109 is a self-delivering RNAi compound (sd-rxRNA) in development to reduce dermal and ocular fibrosis
Focusing on Advances in Immuno-Oncology
These under-$10 stocks are within range of triggering breakout trades.
Stocks with insider trader activity include RXII, MA and SWN
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.